Mainz Biomed (NASDAQ:MYNZ) shares down 8.2%

Mainz Biomed (NASDAQ:MYNZ – Get Free Report) stock price fell by 8.2% during midday trading on Friday. The company traded as low as $0.34 and was last traded at $0.35. About 723,885 shares were traded during midday trading, an increase of 121% compared to the average daily volume of 327,084 shares. The stock previously closed at $0.38.

Analysts set new price targets

Separately, Cantor Fitzgerald reiterated a “neutral” rating on Mainz Biomed shares in a report dated Friday, April 12.

Check out our latest analysis on MYNZ

Mainz Biomed is trading 8.2% lower

The company’s 50-day moving average is $0.56 and its 200-day moving average is $0.84. The company has a current ratio of 0.97, a quick ratio of 0.91 and a debt-to-equity ratio of 0.36.

About Mainz Biomed

(Get free report)

Mainz Biomed NV develops and markets in vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a stool molecular genetic diagnostic test for colorectal cancer. It is also developing PancAlert, a stool-based screening test for the detection of pancreatic cancer.

Featured Stories

Get news and reviews for Mainz Biomed Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Mainz Biomed and related companies with MarketBeat.com’s FREE daily email newsletter.